GlobeNewswire: T2 Biosystems, Inc. Contains the last 10 of 364 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:54:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2854066/0/en/T2-Biosystems-Announces-Extension-of-Multi-Year-Capital-Equipment-Supplier-Agreement-with-Vizient-Inc.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.2024-03-28T13:00:00Z<![CDATA[LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.]]>https://www.globenewswire.com/news-release/2024/03/20/2849273/0/en/T2-Biosystems-Unveils-T2Lyme-Launch-Plans-and-Provides-Additional-Business-Updates.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates2024-03-20T11:30:00Z<![CDATA[Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024]]>https://www.globenewswire.com/news-release/2024/03/19/2848615/0/en/T2-Biosystems-to-Host-Investor-Call-on-March-20-2024-to-Unveil-its-T2Lyme-Launch-Plans-and-Provide-Additional-Business-Updates.html?f=22&fvtc=4&fvtv=22951T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates2024-03-19T13:00:00Z<![CDATA[LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2024/03/18/2847863/0/en/T2-Biosystems-Announces-New-Publication-Highlighting-the-Clinical-Benefits-and-Performance-of-the-T2Resistance-Panel.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel2024-03-18T13:00:00Z<![CDATA[Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes]]>https://www.globenewswire.com/news-release/2024/03/12/2844571/0/en/T2-Biosystems-Receives-Extension-to-Comply-with-Nasdaq-Listing-Requirement.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement2024-03-12T13:00:00Z<![CDATA[LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market, subject to the Company demonstrating compliance with Nasdaq's market value of listed securities (“Market Value”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) on or before May 20, 2024.]]>https://www.globenewswire.com/news-release/2024/02/15/2830381/0/en/T2-Biosystems-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results2024-02-15T21:06:00Z<![CDATA[Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales]]>https://www.globenewswire.com/news-release/2024/02/15/2830361/0/en/T2-Biosystems-Announces-Agreement-with-CRG-for-the-Conversion-of-15-Million-of-CRG-Term-Loan-into-Equity.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity2024-02-15T21:04:00Z<![CDATA[LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a definitive agreement to convert $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity upon stockholder approval.]]>https://www.globenewswire.com/news-release/2024/02/15/2830354/0/en/T2-Biosystems-Announces-Commercial-Expansion-Through-Distributors-in-Europe-and-Asia.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia2024-02-15T21:02:00Z<![CDATA[LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of territory exclusive distribution agreements for new geographies in the Netherlands, Belgium, and Vietnam, as well as the re-entry into Switzerland. Under the terms of the agreements, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel into these countries through our distribution partners.]]>https://www.globenewswire.com/news-release/2024/02/12/2827565/0/en/T2-Biosystems-Receives-FDA-510-k-Clearance-for-the-Expanded-T2Bacteria-Panel.html?f=22&fvtc=4&fvtv=22951T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel2024-02-12T14:00:00Z<![CDATA[Increases number of bacteria species detected with addition of Acinetobacter baumannii Increases number of bacteria species detected with addition of Acinetobacter baumannii]]>https://www.globenewswire.com/news-release/2024/02/07/2825558/0/en/T2-Biosystems-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Updates-on-February-15-2024.html?f=22&fvtc=4&fvtv=22951T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 20242024-02-07T21:05:00Z<![CDATA[LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.]]>